Estimation of Long‐Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX‐ and Virtual Twin‐Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials

Estimation of Long‐Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX‐ and Virtual Twin‐Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials

ABSTRACT The 3‐year placebo‐controlled FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the antifracture efficacy of denosumab in postmenopausal women with osteoporosis. The 7‐year open‐label extension demonstrated that denosumab treatment for up...

Full description

Bibliographic Details
Main Authors: Ethel Siris, Michele McDermott, Nicola Pannacciulli, Paul D Miller, E Michael Lewiecki, Roland Chapurlat, Esteban Jódar‐Gimeno, Shuang Huang, John A Kanis
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:JBMR Plus
Subjects:
DENOSUMAB
FRAX
HIP FRACTURE
OSTEOPOROSIS
OSTEOPOROTIC FRACTURE
Online Access:https://doi.org/10.1002/jbm4.10348

Internet

https://doi.org/10.1002/jbm4.10348

Similar Items